Germany's Merck suffers setback with cancer drug
Linkedin

Germany's Merck suffers setback with cancer drug

Berlin : Germany | Dec 19, 2012 at 3:51 AM PST
Source: Virginian-Pilot Online
XX XX
Views: Pending
 
German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations. The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study. FULL ARTICLE AT Virginian-Pilot Online
1 of 2
Next
Merck KGaA had said that phase III clinical trials of Erbitux for treatment of gastric cancer drug had shown no benefits
Merck KGaA had said that phase III clinical trials of Erbitux for treatment of gastric cancer drug had shown no benefits
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

News Stories

 
  • Merck KGaA, Oncothyreon hit as cancer vaccine fails

      BDNews24
    An experimental lung cancer vaccine from Germany's Merck KGaA failed to improve survival in a pivotal study, dealing a blow to the company and the high-risk field of using vaccines to fight tumors. Stimuvax, which Merck licensed from U.S. biotech...

Images

 >
 

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.